**Specifications Table**TableSubject area*Biology*More specific subject area*Vascular physiology*Type of data*Tables and Figures*How data was acquired*Flow-mediated vasodilation test using ultrasonic diagnostic equipment*Data format*Raw, Analyzed*Experimental factors*The brachial artery was monitored using ultrasonic diagnostic equipment and the diameter was calculated. In addition, blood pressure was assessed.*Experimental features*A cross-over design was utilized. The emu oil/placebo was administered under conditions of dietary restriction to avoid confounding.*Data source location*Abashiri, Japan*Data accessibility*The data are supplied with this article*

**Value of the data**•These data are available to determine the effect of emu oil on blood flow-mediated vasodilation responses and blood pressure.•The data presented here may be used as a reference for comparisons with other foods that have an effect on flow-mediated vasodilation responses and blood pressure.•This data offers a valuable and searchable resource on functional foods and can be used for future functional food studies.

1. Data {#s0005}
=======

Flow-mediated vasodilation is the dilation response of the artery to the shear stress of blood flow, and has been utilized in clinical medicine and functional food studies as a noninvasive method to examine endothelial function [@bib1]. Flow-mediated vasodilation can be represented by the changes in brachial arterial diameter after increased blood flow. To produce the condition of increased blood-flow, pressure can be applied using a pressure cuff and then released by deflating the cuff [@bib2], [@bib3]. [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"} show the changes in the arterial diameter after releasing pressure applied to the antebrachial region via a pressure cuff in emu oil or placebo dosed men and women. [Table 1](#t0005){ref-type="table"} provides the numeric arterial diameter data used to generate the line graphs in [Fig. 1](#f0005){ref-type="fig"}. Blood pressure data are provided in [Table 2](#t0010){ref-type="table"}.Fig. 1Changes in the arterial diameter in emu oil and placebo dosed male participants after releasing pressure applied to the antebrachial region.Fig. 1Fig. 2Changes in the arterial diameter in emu oil or placebo dosed female participants after releasing pressure applied to the antebrachial region.Fig. 2Table 1Changes in the arterial diameter (mm) after releasing pressure applied to the antebrachial region in emu oil and placebo dosed participants.Table 1ParticipantTime (sec)2030405060708090100110MaleAPlacebo3.623.693.783.844.133.903.863.713.663.66Emu oil3.203.293.353.443.513.433.363.253.233.19BPlacebo3.343.423.443.513.543.513.473.413.393.37Emu oil3.223.263.313.333.343.313.283.233.193.07CPlacebo3.883.944.024.044.053.913.893.853.753.71Emu oil3.964.114.214.274.344.264.184.154.124.10DPlacebo3.373.443.423.543.633.623.533.403.343.31Emu oil3.153.293.363.453.483.393.283.223.153.13EPlacebo4.704.794.834.874.934.894.844.754.624.62Emu oil4.134.234.284.334.394.304.254.184.104.03FPlacebo3.513.583.593.703.753.713.693.673.563.53Emu oil3.363.453.493.553.623.603.573.543.493.45GPlacebo3.653.693.723.783.853.773.753.723.683.60Emu oil3.723.813.883.944.024.003.883.843.803.69HPlacebo3.934.064.144.154.154.124.124.063.993.89Emu oil3.423.533.603.663.713.673.603.573.513.47IPlacebo4.144.174.204.274.274.214.154.114.073.99Emu oil3.763.823.903.974.113.893.853.793.743.71JPlacebo3.243.383.313.353.353.353.283.253.233.15Emu oil3.193.323.403.443.453.443.363.323.303.28FemaleAPlacebo3.493.563.633.703.793.723.643.583.513.45Emu oil3.533.613.693.793.823.733.693.653.603.50BPlacebo2.933.003.093.093.123.123.103.103.053.05Emu oil2.662.762.812.842.852.782.722.682.622.58CPlacebo2.332.402.442.462.482.472.452.402.322.30Emu oil2.222.292.352.392.422.392.342.282.262.19DPlacebo3.643.713.783.843.883.853.833.803.793.73Emu oil3.413.503.583.633.773.653.593.533.473.43EPlacebo3.413.463.553.623.653.573.533.513.373.33Emu oil3.103.163.213.263.383.293.203.093.002.97FPlacebo2.412.472.522.602.632.572.512.482.462.42Emu oil3.073.163.203.243.293.173.113.073.042.99GPlacebo3.093.153.203.253.313.223.163.113.073.00Emu oil2.862.903.003.053.093.072.932.892.832.75HPlacebo3.223.293.373.383.443.343.293.253.233.21Emu oil3.003.153.193.233.253.243.203.163.093.04IPlacebo2.382.442.482.522.572.552.532.492.452.44Emu oil2.522.612.672.702.732.692.642.572.532.51JPlacebo3.003.073.143.163.253.113.073.023.002.96Emu oil2.942.993.033.133.133.042.902.882.842.82Table 2Blood pressure in emu oil and placebo dosed participants.Table 2Blood Pressure (mmHg)SystolicDiastolicParticipantPlaceboEmu oilPlaceboEmu oilMaleA1151137264B1221256767C1211236265D1261355651E1151176359F1161186867G1181216561H1091106668I110976454J1141115658FemaleA1111107475B95975657C1031016361D1111006459E98975553F1071036768G981007169H96986357I1081126970J1221237672

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Participants {#s0015}
-----------------

Twenty healthy students (10 males and 10 females; age range, 19--21 years) from the Hokkaido Okhotsk Campus of the Tokyo University of Agriculture were recruited in July 2017, according to the inclusion and exclusion criteria shown in [Supplementary Document 1](#s0050){ref-type="sec"}. The study protocol was approved by the Tokyo University of Agriculture Committee of Human Subject Research Ethics. Informed consent was obtained from all participants.

2.2. Materials {#s0020}
--------------

Edible emu oil, extracted from the subcutaneous fat of the emu (*Dromaius novaehollandiae*), was purchased from Tokyo NODAI Bio-Industry (Abashiri, Japan). Fifty milligrams of the oil were encapsulated into soft gelatin capsules (Matsuya, Osaka, Japan). Dose of emu oil was determined based on the amount in blending quantity in the commercially available emu oil capsule, to avoid the unexpected side effect due to emu oil even though the possible side effect has not found in the oil.

2.3. Food restriction protocol and flow-mediated vasodilation measurement {#s0025}
-------------------------------------------------------------------------

The data were collected at the Hokkaido Okhotsk Campus of the Tokyo University of Agriculture between July and August 2017. Using a cross-over design, each participant was randomly administered a single dose of the emu oil or tap water (placebo) in a soft capsule. The second dose of the capsule, which is another sample from single dose, was administered more than a week later. Participants were asked not to take any nutritional supplements on the day before and the morning of the test, with the exception of 90--130 g/meal of cereal (Flugra, Calbee, Tokyo, Japan) and 600--800 mL/day of milk, to meet Dietary Reference Intakes for Japanese 2015 from Ministry of Health, Labour and Welfere of Japan.

Flow-mediated vasodilation was measured 3 h after the oil was administered. Precise criteria for the measurement based on the Guidelines for non-invasive vascular function test [@bib4] is described in [Supplementary document 2](#s0050){ref-type="sec"}. To arrest the blood flow in the brachial artery, pressure (blood pressure plus 40 mmHg) was applied to the antebrachial region for 5 min using the cuff of a mercurial sphygmomanometer (Yamasu, Japan). Avascularization was monitored by using color Doppler option of ultrasonic diagnostic equipment (LOGIQ P6, GE Healthcare, Little Chalfont, UK). The pressure was released by deflating the cuff, and the brachial artery was monitored continuously using LOGIQ P6. Electro-cardiogram was concomitantly monitored to detect diastolic potential. Arterial diameter (AD) when the maximum diastolic potential was measured using the custom-designed edge-detection software FMDscope (Media Cross Co. Ltd, Japan). The AD was determined based on average of 10-times measurements. Potential error in measurements was detected by using trend graph of AD, and omitted from the calculation of average score. Blood pressure was measured using an electronic sphygmomanometer (ES-P2000, Terumo, Tokyo, Japan). We confirmed that no significant side effect was observed from any participant in this study.
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